British firm behind Centrum, Sensodyne worth $36B

By Agence France-Presse

Jul 19, 2022 12:04 am

LONDON: Haleon, the consumer health care unit spun off by United Kingdom drug giant GlaxoSmithKline (GSK), was worth about £31 billion ($36 billion) when it began trading in London on Monday.

The new company — which owns brands that include Sensodyne toothpaste, pain-relief drug Panadol and cold treatment Theraflu — was worth lower than an expected £40 billion, with its shares down 5 percent.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

Malaysia, Singapore announce SEZ deal

Indonesia joins Brics bloc

Samsung Q4 earnings hit by AI chip supply delay

Nvidia CEO unveils new gaming chips

Toyota backs Japanese space startup IST

US calls out Tencent, CATL for ties to PLA

Caixin services PMI comes in at 52.2